Previous Close | 4.91 |
1-Year Change | -74.61% |
6-Months Change | -59.42% |
3-Months Change | -40.05% |
Moving Avg (50d) | 6.802 |
Moving Avg (200d) | 12.0569 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 300.4M |
Beta (3-Years) | 1.22 |
Revenue Growth (ttm) | 837.52% |
Net Profit Margin (ttm) | -317.29% |
Return On Assets (ttm) | -54.24% |
EPS (ttm) | -5.57 |
PE Ratio (ttm) | -0.88 |
Dividend Yield | 0% |
Asset Description: | Sage Therapeutics, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Strong sell |
Forecast Date: | 2024-11-14 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
5.008 | 5.155 | 5.254 | 5.401 | 5.646 | 5.892 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.